{"id":351,"date":"2023-03-17T11:10:22","date_gmt":"2023-03-17T11:10:22","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=351"},"modified":"2023-04-24T13:46:57","modified_gmt":"2023-04-24T12:46:57","slug":"pearls","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=351","title":{"rendered":"PEARLS"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

PEARLS: A phase II\/III trial of primary radiotherapy for androgen sensitive prostate cancer patients with lymph nodes<\/p>\n\n\n\n

Trial summary:<\/h2>\n\n\n\n

PEARLS aims to determine whether extended field IMRT to the prostate, pelvis and para-aortic region improves metastasis-free survival compared to standard field IMRT to the prostate \u00b1 pelvis in patients with node positive prostate cancer. PSMA PET-CT imaging is used to determine the extent of lymph node disease and to identify involved lymph nodes for an integrated RT boost.  893 patients will be recruited from 30 UK sites over 6.5 years.<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td>Streamlined<\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>Streamlined<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>Extended field arm case<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>For extended field arm<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>PACE, PIVOTALboost and PACE-NODES trials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact: pearls.rtqa@nhs.net <\/p>\n\n\n\n

Chief investigator: Dr Julia Murray<\/p>\n\n\n\n

Sponsor: The Institute of Cancer Research (pearls-icrctsu@icr.ac.uk)<\/p>\n\n\n\n

Funder: Cancer Research UK<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

PEARLS: A phase II\/III trial of primary radiotherapy for androgen sensitive prostate cancer patients with lymph nodes Trial summary: PEARLS aims to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-351","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=351"}],"version-history":[{"count":3,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/351\/revisions"}],"predecessor-version":[{"id":365,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/351\/revisions\/365"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}